Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Pancreatic Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Unspecified Childhood Solid Tumor, Protocol Specific 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Oligodendroglioma 1Myelodysplastic Syndromes 1Metastatic Castration-Resistant Prostate Cancer Patients 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Kidney Neoplasms 1Gliosarcoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Carboplatin 87Paclitaxel 77Bevacizumab 38Topotecan 23liposomal doxorubicin 22Gemcitabine 22Taxes 21Cisplatin 17Drug Therapy 14Docetaxel 14Cyclophosphamide 14pembrolizumab 13Immunoglobulin G 12Disulfides 12veliparib 8rucaparib 8mirvetuximab soravtansine 8niraparib 7Albumin-Bound Paclitaxel 7sargramostim 6Filgrastim 6Erlotinib Hydrochloride 6Doxorubicin 6pazopanib 5Granulocyte-Macrophage Colony-Stimulating Factor 5Chemotherapy, Adjuvant 5CP protocol 5trebananib 4temsirolimus 4olaparib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Fallopian Tube Neoplasms × irofulven × Clear all
NCT00019552 2013-06-20

Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡